It was demonstrated that mouse or human tumors with forced expression of membrane-bound NKG2D ligands can be rejected in vivo through activation of NK cells and sometimes CD8 T cells, heightening the significance of NKG2D stimulating in anti-tumor immunity [14,15]. The gene discussed is KLRK1; the disease is neoplasm.